Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breakthrough cancer pain: an observational study of 1000 European oncology patients.
Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, Slama O, Korhonen T, Filbet M, Poulain P, Mystakidou K, Ardavanis A, O'Brien T, Wilkinson P, Caraceni A, Zucco F, Zuurmond W, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund KF, Stenberg M. Davies A, et al. Among authors: ardavanis a. J Pain Symptom Manage. 2013 Nov;46(5):619-28. doi: 10.1016/j.jpainsymman.2012.12.009. Epub 2013 Mar 22. J Pain Symptom Manage. 2013. PMID: 23523361 Free article.
Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A, Ardavanis A, Koumakis G, Samantas E, Psyrri A, Papadimitriou C. Kotsakis A, et al. Among authors: ardavanis a. BMC Cancer. 2019 Jan 18;19(1):88. doi: 10.1186/s12885-019-5301-5. BMC Cancer. 2019. PMID: 30658600 Free PMC article.
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: ardavanis a. Ann Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193. Ann Oncol. 2019. PMID: 31228203 Free article.
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Kakolyris S, et al. Among authors: ardavanis a. Oncology. 2008;74(1-2):31-6. doi: 10.1159/000138977. Epub 2008 Jun 10. Oncology. 2008. PMID: 18544957 Clinical Trial.
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group. Mavroudis D, et al. Among authors: ardavanis a. Ann Oncol. 2010 Jan;21(1):48-54. doi: 10.1093/annonc/mdp498. Epub 2009 Nov 11. Ann Oncol. 2010. PMID: 19906761 Free article. Clinical Trial.
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D. Pallis AG, et al. Among authors: ardavanis a. Ann Oncol. 2012 May;23(5):1164-1169. doi: 10.1093/annonc/mdr405. Epub 2011 Sep 21. Ann Oncol. 2012. PMID: 21937705 Free article. Clinical Trial.
ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
Koumarianou A, Makrantonakis P, Zagouri F, Papadimitriou C, Christopoulou A, Samantas E, Christodoulou C, Psyrri A, Bafaloukos D, Aravantinos G, Papakotoulas P, Baka S, Andreadis C, Alexopoulos A, Bompolaki I, Kampoli Κ, Liori S, Karvounis K, Ardavanis A. Koumarianou A, et al. Among authors: ardavanis a. Breast Cancer Res Treat. 2020 Jul;182(1):85-96. doi: 10.1007/s10549-020-05677-4. Epub 2020 May 16. Breast Cancer Res Treat. 2020. PMID: 32418045
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Ardavanis A, et al. Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. doi: 10.1007/s00280-006-0236-3. Epub 2006 May 23. Cancer Chemother Pharmacol. 2006. PMID: 16718470 Clinical Trial.
Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental.
Papakotoulas P, Tsoukalas N, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C, Papatsimpas G, Papakostas P, Samelis G, Andreadis C, Aravantinos G, Ziras N, Kalofonos C, Samantas E, Souggleri M, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Tripodaki S, Bokas A, Grivas A, Timotheadou E, Bournakis E, Varthalitis I, Boukovinas I. Papakotoulas P, et al. Among authors: ardavanis a. Anticancer Res. 2020 Jan;40(1):305-313. doi: 10.21873/anticanres.13954. Anticancer Res. 2020. PMID: 31892581
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" study).
Alexopoulos A, Karanikiotis C, Ardavanis A, Boukovinas I, Makrantonakis P, Papadimitriou C, Athanasiadis A, Boutis A, Giassas S, Kakolyris S, Koumakis G, Papazisis K, Psyrri A, Ziras N, Baka S, Kentepozidis N, Michalaki V. Alexopoulos A, et al. Among authors: ardavanis a. Anticancer Res. 2022 Feb;42(2):1031-1041. doi: 10.21873/anticanres.15564. Anticancer Res. 2022. PMID: 35093904
124 results